A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cytokinetics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 166,800 shares of CYTK stock, worth $8.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
166,800
Previous 141,200 18.13%
Holding current value
$8.09 Million
Previous $7.65 Million 15.12%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$51.22 - $60.16 $4.01 Million - $4.71 Million
78,218 Added 9.11%
937,191 $49.5 Million
Q2 2024

Aug 14, 2024

BUY
$47.86 - $75.05 $14.3 Million - $22.4 Million
298,071 Added 53.14%
858,973 $46.5 Million
Q1 2024

May 15, 2024

BUY
$63.75 - $108.06 $18.4 Million - $31.2 Million
288,309 Added 105.77%
560,902 $39.3 Million
Q4 2023

Feb 14, 2024

SELL
$26.88 - $83.49 $25.8 Million - $80.1 Million
-959,231 Reduced 77.87%
272,593 $22.8 Million
Q3 2023

Nov 14, 2023

BUY
$29.46 - $36.61 $9.78 Million - $12.1 Million
331,835 Added 36.87%
1,231,824 $36.3 Million
Q2 2023

Aug 14, 2023

BUY
$32.62 - $40.75 $29.4 Million - $36.7 Million
899,989 New
899,989 $29.4 Million
Q4 2022

Feb 14, 2023

SELL
$35.77 - $51.11 $14.9 Million - $21.3 Million
-417,392 Reduced 83.87%
80,263 $3.68 Million
Q3 2022

Nov 14, 2022

SELL
$38.54 - $54.52 $160 Million - $226 Million
-4,145,172 Reduced 89.28%
497,655 $24.1 Million
Q2 2022

Aug 15, 2022

BUY
$33.93 - $48.92 $148 Million - $214 Million
4,370,177 Added 1602.85%
4,642,827 $182 Million
Q1 2022

May 16, 2022

BUY
$29.74 - $46.0 $7.16 Million - $11.1 Million
240,717 Added 753.82%
272,650 $10 Million
Q4 2021

Feb 14, 2022

SELL
$34.35 - $46.38 $8.99 Million - $12.1 Million
-261,674 Reduced 89.12%
31,933 $1.46 Million
Q3 2021

Nov 15, 2021

BUY
$18.54 - $35.74 $3.83 Million - $7.38 Million
206,533 Added 237.19%
293,607 $10.5 Million
Q2 2021

Aug 16, 2021

SELL
$19.79 - $26.99 $4.64 Million - $6.33 Million
-234,642 Reduced 72.93%
87,074 $1.72 Million
Q1 2021

May 17, 2021

BUY
$18.57 - $25.68 $4.11 Million - $5.69 Million
221,545 Added 221.17%
321,716 $7.48 Million
Q4 2020

Feb 16, 2021

SELL
$15.26 - $28.61 $18.3 Million - $34.4 Million
-1,201,778 Reduced 92.31%
100,171 $2.08 Million
Q3 2020

Nov 16, 2020

BUY
$20.58 - $28.96 $12.8 Million - $18 Million
622,924 Added 91.74%
1,301,949 $28.2 Million
Q2 2020

Aug 14, 2020

SELL
$11.15 - $24.64 $5.42 Million - $12 Million
-485,691 Reduced 41.7%
679,025 $16 Million
Q1 2020

May 15, 2020

BUY
$8.75 - $16.3 $9.81 Million - $18.3 Million
1,121,024 Added 2565.74%
1,164,716 $13.7 Million
Q4 2019

Feb 14, 2020

SELL
$7.95 - $11.84 $85,907 - $127,943
-10,806 Reduced 19.83%
43,692 $464,000
Q3 2019

Nov 14, 2019

BUY
$10.82 - $14.25 $32,016 - $42,165
2,959 Added 5.74%
54,498 $620,000
Q2 2019

Aug 14, 2019

SELL
$7.95 - $11.25 $755,965 - $1.07 Million
-95,090 Reduced 64.85%
51,539 $580,000
Q1 2019

May 15, 2019

SELL
$5.95 - $10.19 $439,252 - $752,266
-73,824 Reduced 33.49%
146,629 $0
Q4 2018

Feb 14, 2019

BUY
$5.91 - $9.29 $921,085 - $1.45 Million
155,852 Added 241.25%
220,453 $1.39 Million
Q2 2018

Aug 10, 2018

SELL
$6.9 - $9.9 $1.43 Million - $2.06 Million
-207,868 Reduced 76.29%
64,601 $0
Q1 2018

May 11, 2018

SELL
$7.2 - $10.05 $1.08 Million - $1.5 Million
-149,708 Reduced 35.46%
272,469 $1.96 Million
Q4 2017

Feb 09, 2018

SELL
$7.25 - $15.65 $6 Million - $13 Million
-828,120 Reduced 66.23%
422,177 $3.44 Million
Q3 2017

Nov 09, 2017

BUY
$12.0 - $15.0 $15 Million - $18.8 Million
1,250,297
1,250,297 $18.1 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.57B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.